Drugs / MLD10
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT02322333 Comparator | Mar 2015 → Jun 2017 | migraine disorder | Pharmalyte Solutions LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLD10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02322333 ↗ |
| Known as | magnesium L-lactate dehydrate | “Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment.” NCT02322333 ↗ |
| Route | Oral | “Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day.” NCT02322333 ↗ |